Preclinical News and Research

RSS

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

NexMed raises $2.3M through private placement

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed’s option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.

9 Feb 2010

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.

9 Feb 2010

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Cancer Research UK's commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

9 Feb 2010

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avram Cooperman.

6 Feb 2010

Results validating performance of GSN’s proprietary Parental Support technology published

Gene Security Network, Inc (GSN) today announced that Human Reproduction published results validating the exceptional performance of GSN’s proprietary Parental SupportTM technology over existing methods to detect chromosome abnormalities during in vitro-fertilization (IVF).

5 Feb 2010

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.

5 Feb 2010

Implanted ventricular assist heart pump for infants project awarded $5.6M federal contract

Researchers at the University of Pittsburgh and their collaborators have been awarded a $5.6 million federal contract to pursue the continued development of an implanted ventricular assist heart pump for infants and small children with congenital or acquired heart disease. The project aims to provide much-needed access to the sophisticated technologies that have saved the lives of older heart failure patients.

5 Feb 2010

Researchers evaluate ethical and legal issues of volunteers who participate in endoscopy-based studies

The involvement of healthy volunteers (HV) in clinical and preclinical research, especially in the gastroenterology, has grown dramatically over the past few years. However, many issues of ethical, methodological or even legal concerns have not been systematically studied.

5 Feb 2010

NHLBI awarded four contracts to test new devices to help children with congenital heart defects

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has awarded four contracts totaling $23.6 million to begin preclinical testing of devices to help children born with congenital heart defects or those who develop heart failure.

5 Feb 2010

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

1st Annual Biliary Tract-Gallbladder Cancer Research Symposium to be held at ASCO in Alexandria

CanLiv: The Hepatobiliary Cancers Foundation in partnership with The Cholangiocarcinoma Foundation will host the 1st Annual Biliary Tract-Gallbladder Cancer Research Symposium on Friday, May 7, 2010 at the American Society of Clinical Oncologists (ASCO) headquarters in Alexandria, Virginia.

4 Feb 2010

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.

4 Feb 2010

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

4 Feb 2010

HUCB-derived purified and expanded CD133+ cells may show promise in cellular cardiomyoplasty

Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.

4 Feb 2010

Preclinical News and Research

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

NexMed raises $2.3M through private placement

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

AMRI announces fourth-quarter and full-year 2009 results

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Results validating performance of GSN’s proprietary Parental Support technology published

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Implanted ventricular assist heart pump for infants project awarded $5.6M federal contract

Researchers evaluate ethical and legal issues of volunteers who participate in endoscopy-based studies

NHLBI awarded four contracts to test new devices to help children with congenital heart defects

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

1st Annual Biliary Tract-Gallbladder Cancer Research Symposium to be held at ASCO in Alexandria

PLX cell therapy may be an effective treatment for ischemic stroke disorder

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

HUCB-derived purified and expanded CD133+ cells may show promise in cellular cardiomyoplasty

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics